Shenzhen JYMed Technology Co., Ltd.

Recently, Hubei JXBio Pharmaceutical Co., Ltd. (“Hubei JXBio”), the peptide manufacturing base of Jianyuan Pharmaceuticals, received the Chemical API Marketing Approval Notification for Icatibant Acetate (Registration No.: Y20240000910) issued by the National Medical Products Administration (NMPA), approving the domestic manufacturing and marketing of the API. Icatibant Acetate is a selective bradykinin B2 receptor antagonist indicated for the acute treatment of hereditary angioedema (HAE) in adults, adolescents, and pediatric patients aged 2 years and older. As the registered holder of this API, Hubei JXBio has successfully completed the regulatory review and obtained marketing approval, thereby supporting its client in advancing the commercialization of the corresponding formulation. This approval further validates the Company’s compliance manufacturing capabilities and quality system strengths in the peptide API sector. To date, the Hubei JXBio peptide manufacturing facility has successfully passed two US FDA cGMP inspections, one EAEU GMP inspection, and multiple NMPA cGMP inspections, earning recurrent international recognition for its quality management system. The Company’s major products have been filed in multiple established markets including the U.S., the EU, and South Korea, positioning it to compete in the global supply chain. Shenzhen JYMed Technology Co., Ltd. A leading global peptide solutions provider

JYMed is pleased to announce that the U.S. Food and Drug Administration has acknowledged receipt of a new Type II Drug Master File for semaglutide API manufactured under a new process. FDA acknowledgment letter for JYMed’s Type II DMF filing for semaglutide API submitted under a new process in February 2026. This filing reflects our continued commitment to strengthening technical capabilities, process development, and regulatory support for complex peptide APIs. As global demand for high-quality semaglutide continues to grow, JYMed remains focused on supporting partners with robust manufacturing expertise, regulatory documentation, and scalable supply solutions. The newly filed DMF further demonstrates JYMed’s ongoing investment in peptide process optimization and regulatory readiness. For partners evaluating long-term supply strategies, this milestone supports broader confidence in our ability to advance high-standard manufacturing programs for strategically important peptide APIs. At JYMed, we continue to expand our platform for peptide development and manufacturing, with a focus on quality, consistency, and international regulatory support. We look forward to continuing to support customers seeking reliable peptide API partners for both current and future pipeline needs. Important Disclaimer:The FDA’s acknowledgment of the new semaglutide active pharmaceutical ingredient process is only a necessary preliminary regulatory step. Final market approval and international commercialization remain subject to further complex review and registration procedures, and the timing and outcome of those processes are uncertain. To learn more about JYMed’s peptide API and CDMO capabilities, contact our team to discuss your peptide development needs.

Sustainable peptide manufacturing is rapidly becoming a priority in the pharmaceutical industry. The rapid global expansion of peptide therapeutics in metabolic and chronic disease treatment is accelerating the need for more efficient and environmentally responsible production models. As peptide therapeutics expand into metabolic diseases, oncology, neurology, and cosmetic applications, manufacturers must balance innovation with environmental responsibility. As a peptide-focused CRDMO with more than 16 years of specialization, JYMed Technology Co., Ltd. integrates sustainability and green chemistry principles directly into its manufacturing platforms and facility design. Traditional peptide production relies on solvent-intensive reactions, energy-heavy purification, and complex chemical processes. Today, green chemistry in pharma is redefining how peptide CDMOs design, scale, and optimize manufacturing systems. Sustainability is no longer optional — it is a competitive and regulatory requirement. Green chemistry in pharmaceutical manufacturing refers to designing chemical processes that reduce environmental impact while improving efficiency and safety, following internationally recognized green chemistry principles. At JYMed, green synthesis strategies such as Minimum Protecting Group methodologies and continuous purification systems are applied to balance efficiency, scalability, and environmental responsibility. This includes: Lower solvent consumption Reduced hazardous reagents Waste minimization strategies Energy-efficient purification systems Scalable and repeatable synthesis workflows Eco-friendly peptide production not only benefits the environment but also improves yield consistency, reduces operational costs, and enhances regulatory compliance. Understanding the environmental footprint of peptide manufacturing is essential for improvement. Key challenges include: Multiple washing and purification cycles increase chemical consumption and disposal requirements. Excess orthogonal protecting groups generate reagent waste and side reactions. Freeze drying and chromatographic processes consume significant energy if not optimized. Poorly optimized lab methods multiply waste and cost when transferred to commercial scale. Addressing these issues is fundamental to achieving sustainable peptide CDMO operations. Reducing unnecessary protecting groups is one of the most effective green peptide synthesis techniques. Benefits include: Shorter reaction cycles Lower reagent consumption Reduced chemical waste Improved process predictability This strategy directly supports eco-friendly peptide production while maintaining high purity standards. This approach also contributes to reducing Process Mass Intensity (PMI) in peptide synthesis, a key sustainability metric in pharmaceutical manufacturing. Continuous purification systems are replacing traditional batch chromatography to support sustainable pharmaceutical manufacturing. Advantages include: Reduced solvent usage Higher throughput efficiency Better industrial scalability Lower environmental footprint Spray drying and optimized lyophilization methods also contribute to energy-efficient peptide processing. Advanced analytical platforms significantly impact sustainable peptide manufacturing. Intelligent analytical systems help: Prevent failed batches Reduce repeat synthesis runs Optimize purification cycles Increase overall yield Higher yield equals lower waste, making analytical precision a core element of green chemistry pharma initiatives. Sustainable peptide manufacturing extends beyond chemistry into facility engineering. Modern peptide CDMOs invest in: Automated reactor systems Optimized plant layouts Scalable pilot-to-commercial equipment Energy-efficient freeze-drying and purification units Smart infrastructure reduces idle energy consumption and supports long-term ESG and sustainable API manufacturing goals. JYMed’s integrated R&D, API, and finished dosage facilities are designed to support scalable peptide production while maintaining strict energy efficiency and regulatory compliance standards. Environmental, Social, and Governance (ESG) metrics increasingly influence procurement decisions in the pharmaceutical sector. Sustainable peptide CDMO partners are evaluated based on: Environmental responsibility Ethical governance Labor and human rights standards Sustainable procurement policies High ESG performance signals operational maturity, risk management strength, and long-term reliability. Eco-friendly peptide production delivers measurable commercial advantages: Lower long-term manufacturing costs Improved regulatory confidence Stronger brand alignment with biotech partners Enhanced global supply chain resilience Competitive differentiation in EU and US procurement markets Sustainability is not just environmental — it is strategic and financial. The next generation of sustainable peptide manufacturing will focus on: AI-driven reaction optimization Greener solvent alternatives Continuous manufacturing systems Nanoparticle and advanced delivery platforms Circular chemical recovery systems These innovations aim to make peptide therapeutics both clinically effective and environmentally responsible. Sustainable peptide manufacturing represents the convergence of scientific innovation, operational efficiency, and environmental accountability — a philosophy that JYMed Technology Co., Ltd. applies across its global peptide CRDMO operations. Green chemistry in pharma is transforming how peptide CDMOs design synthesis platforms, purification technologies, and facility infrastructure. As ESG expectations rise and regulatory standards evolve, sustainable peptide manufacturing will become the benchmark for pharmaceutical excellence. Companies that integrate sustainability into their manufacturing strategies today are positioning themselves as leaders in the future of peptide therapeutics. JYMed Technology Co., Ltd.A Leading Global Peptide Solutions Provider.